Glycine (G) infusion causes renal vasodilation mediated by nitric oxide (NO). Cyclosporine A (CsA) nephrotoxicity is characterized by preglomerular vasoconstriction and decreased efferent arteriolar tone probably related to reduced NO and angiotensin II, respectively. L-Arginine (ARG) is a precursor to NO.
Introduction
While ofundeniable usefulness in clinical medicine, the administration of cyclosporine A (CsA') is encumbered by deleteri-elucidated. One contemporary hypothesis invokes CsA-mediated endothelial damage as a direct antecedent to glomerular hypoperfusion. Indeed, CsA is toxic to endothelial cells in vitro (8) , and preliminary reports suggest impaired endotheliumdependent relaxation in renal and systemic vessels after prolonged CsA exposure (9-1 1 ). It is plausible, therefore, that endothelial dysfunction with reduced activity of the endothelial-derived relaxing factor, nitric oxide (NO), might underlie the functional effect of CsA on glomerular filtration.
Other recent evidence indicates that NO interacts with angiotensin II (All) to govern glomerular hemodynamics and tubular function in normal rats ( 12 ) . Endogenous NO attenuates the glomerular effects of All and is required to permit normal proximal tubular reabsorption. Furthermore, NO mediates an increase in GFR during amino acid infusion, with glomerular and tubular responses to amino acid loading dependent on the balance between NO and All ( 12) . Therefore, it is reasonable to employ the renal response to infusion of the amino acid glycine to test the capacity ofthe kidney to generate NO and to assess the state of NO/All balance in vivo.
The role ofthe renin-angiotensin system in CsA nephrotoxicity remains controversial and probably varies with the duration of CsA administration (6, (13) (14) (15) . Data from this laboratory have demonstrated that short-term chronic CsA administration leads to an imbalance between pre-and postglomerular resistances and a decrease in effective filtration pressure, a scenario compatible with a diminished All response (6) . Because afferent arteriolar resistance is influenced by several mediators, while efferent arteriolar resistance is governed primarily by All, the functional effects of chronically administered CsA on the kidney may involve an inadequate efferent arteriolar All response to preglomerular vasoconstriction. This hypothesis has not been tested by direct measurement of intrarenal All concentrations.
Chronic ingestion of L-arginine reduces blood pressure in hypertensive rats (16) (17) (18) and delays the progression of renal disease in rats with remnant kidneys (19) by mechanisms which remain undefined. In that L-arginine is a substrate for the synthesis of NO (20) , the salutary influence of L-arginine on blood pressure and renal function may be mediated by NO. We therefore assessed the response to glycine infusion in the CsA nephrotoxic model in the rat and the capacity of arginine to potentially normalize the response to glycine in order to (a) evaluate the glomerular and tubular responses to glycine infusion in CsA treated rats, (b) determine the potential for L-arginine feeding to modify the response to glycine, and (c) estimate the impact ofCsA and L-arginine on intrarenal All by direct measurement.
Methods
Experiments were conducted in 53 male Munich-Wistar rats ( 180-220 g body wt) obtained from Simonsen Laboratories (Gilroy, CA). Animals were allowed free access to tap water. During the 8-d protocol period, rats treated with CsA and their pair-fed counterparts ate 16 g/24 h ofstandard rat laboratory diet. This dietary protocol was chosen on the basis ofour previous report (6) and preliminary studies showing rats undergoing CsA treatment eat an average of 16 g/d. Four groups of rats were studied. Group CsA, (n = 13) received CsA (Sandoz Pharmaucetical Morris Plains, NJ) at the dose of 30 mg/kg body wt administered in olive oil by daily subcutaneous injection for eight consecutive days before micropuncture. Group A/CsA (n = 17), received parenteral CsA and oral L-arginine ( 1.6 g/kg per d) mixed with their normal diet. Similar doses of L-arginine in the drinking water reduce blood pressure in hypertensive rats ( 16) . Pair-fed control groups, CON (n = 12) and A/CON (n = 12), were injected with olive oil, A/CON also receiving L-arginine in a dose similar to A/CsA group.
Micropuncture studies
Seven rats in group CsA, seven rats in group A/CsA, six rats in group CON, and six rats in group A/CON underwent micropuncture. The animals were allowed free access to food and tap water until the morning of the experiment.
Micropuncture was performed according to protocols previously described in publications from this laboratory (21, 22) . After Inactin (BYK, Constance, FRG) anesthesia (100 mg/kg i.p.) and tracheostomy (PE 240), catheters (PE 50) were placed in the right jugular vein, left femoral artery, urinary bladder, and left ureter. Body temperature was regulated by a servocontrolled heating table. Euvolemic conditions were reconstituted with donor rat plasma as surgical replacement ( 1 ml/ 100 g body wt over 60 min, followed by continuous infusion, 0.15 ml/ 100 g body wt/h). All animals also received Ringers' saline containing 140 Two-period studies were employed to test the response to glycine in each animal. During the first, or baseline (B) period, each animal received an additional infusion of Ringers' saline ( 1.4 ml/h). During a 30-min reequilibration period and throughout the second experimental period each animal received glycine (G) (2.66 M in Ringers' saline at 1.4 ml/h). Data collected during each experimental period involved pressure measurements from three glomeruli and three efferent arterioles, two systemic and three efferent arteriolar plasma samples, and five tubular fluid collections. Measurements and samplings were performed within a span of 60 min.
To investigate if arginine feeding modified the glomerular and tubular response to glycine through a NO-dependent mechanism, the effect of the NO synthase inhibitor NG monomethyl L-arginine (L-NMMA) was evaluated in four additional A/CsA rats. SNGFR and APR were measured during baseline period and during the simultaneous infusion of glycine (2. 66 M in Ringer's at 1.4 ml/h) plus L-NMMA (0.5 mg/kg per min).
Determination ofplasma and renal angiotensin II levels Plasma and renal tissue angiotensin II concentrations were measured in samples obtained after micropuncture and from additional Inactinanesthetized rats pretreated with CsA and arginine, but not subjected to micropuncture.
Plasma processing. 1.0 ml of blood was collected in a syringe containing 20 ,d of EDTA (0.16 M) and 10 MAl of converting enzyme inhibitor (0.1 mM). Samples were spun at 40C and plasma stored at -70'C until processed. Plasma was extracted using a Bondelut Ci8 column previously washed with methanol and triethylamine-formic acid. The column was rinsed with triethylamine formic acid buffer and All was eluted off with acetonitrile triethylamine formic acid 70:30, Iyophilized on a Speed-Vac overnight, and kept at -20'C until assayed. This extraction procedure yielded 92% recovery of All. Renal tissue processing. Kidneys were perfused free of blood with 50 ml of a solution containing 4.9 mM 8-hydroxyquinoline hemisulfate, 2.6 mM EDTA and 3% BSA administered through an aortic catheter. Bloodless kidneys were excised, placed in a plastic container, flash-frozen in liquid nitrogen, and stored at -70'C until further processing. Individual whole kidneys were homogenized (Polytron, Brinkmann Instruments Inc., Westbury, NY; 10 at setting 6) in 2 ml of RIA-BSA 0.25% buffer, added to 9 ml of homogenizing medium (1 N glacial acetic acid, 0.02 N hydrochloric acid, and 0.1% 2 mercaptoethanol), and heated to 90'C for 10 min, then centrifuged at 30,000 g for 20 min. The supernatant, s,, was removed and the pellet resuspended in 4.5 ml of homogenizing medium and centrifuged at 30,000 g for 20 min. The supernatant was combined with s,, and lyophilized overnight using a Speed Vac centrifuge (model RH200-12, Savant Instruments Inc., Farmingdale, NY). The resulting lyophylisate was resuspended in 2 ml of RIA-BSA 0.25% buffer and 500 Al of this extracted using a Bondelut Cl8 column as described above for plasma. This combined procedure yielded 56% recovery of All.
RIA. Lyophylisate was resuspended in 500 gl of RIA buffer and 200 M1 of this was added to 100 Ml of specific rabbit AII-antibody (Ab 127, provided by Dr. Wylie Vale, Salk Institute, La Jolla, CA) diluted 1/62,500. After incubating for 2 d at 4°C, 100 Ml of '25I-AII (6, 000 cpm) (New England Nuclear, Boston, MA), were added to each tube and incubated again at 4°C overnight. All bound to antibody was separated from unbound using normal rabbit serum diluted 1/200 (100 Al), goat anti-rabbit IgG diluted 1/40 (100 ML) and 500 Ml of 10% polyethylene glycol in RIA buffer added to each tube. Tubes were incubated at 4°C for 2 h and then spun for 30 min, the supernatant was decanted, and the pellet was counted in a gamma counter (Searle model 1185, T. M. Analytic, Elk Grove Village, IL, 80% efficiency). All concentrations were calculated using a computer aided logit/log transformation of the standard curve. Cross-reactivity of this All antibody with angiotensin I is 0.33% and with angiotensin III is 68%. Plasma and kidney samples were equally divided in four different assays. Interassay error was 15%.
HPLC. A Beckman (altex) 450 Data/System controller with a 210 variable X detector and two 1 14M pumps were utilized. The altex 21OA injector valve was fitted with a 500-Ml sample loop. Solution A was 0.1% trifluoracetic acid in HPLC grade water. Solution B was 80% acetonitrile, 0.1% trifluoroacetic acid. For HPLC, lyophilized tissue extracts estimated to contain 250 pg of All, 250 pg of synthetic All (Sigma Laboratories, St Louis, MO), or tissue extracts with added synthetic All (total 500 pg) was reconstituted in 500 Ml 20% solution B. A 500-Ml quantity of each was injected into a Vydac C,8 5-Mm reversephase column equilibrated to 20% solution B. A 20-min gradient was run to 40% solution B followed by isocratic run for 7 min. Each run was preceded and followed by a blank gradient to elute any material bound to the column from the previous run. The flow rate was 1 ml/min and 1-min fractions were collected in polypropylene tubes containing 0.1% BSA. The tubes were lyophilized and maintained at -20°C until RIA. All samples (synthetic All, kidney tissue and kidney tissue + All) eluted with a similar pattern with a peak maximum activity at 15 min.
Recovery was 45% for synthetic All, 52% for CON, 59% for CSA, 43% in CON + synthetic All, and 41% for CSA + synthetic All.
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Calculations
The determinants of SNGFR are as follows (21, 25) 
Statistical analysis
For parameters measured once during an experimental period, the effects oftreatments for all two-period studies were analyzed by ANOVA with design for repeated measures (26) . For parameters measured more than once during an experimental period, (SNGFR, APR, FR, PG, PUS, HPE, and AP) effects were analyzed by standard three-way ANOVA using individual measurements. In the subsequent text, mention of the "main effect" of a treatment refers to the main effect, by ANOVA, on groups receiving that treatment. Student's t test was also applied to certain intergroup comparisons as appropriate. All results are expressed as mean±SEM and statistical significance was defined as P < 0.05.
Results
Body weight at the start of pair-feeding did not differ between groups (230±5,244±8,219±13, and 240±6 g for CsA, A/CsA, CON, and A/CON, respectively). Body weight did not change significantly during the LpA among the subset of animals receiving CsA. As a result, ARG did not condition the effect of CsA on SNGFR. The administration ofARG to control rats had no discernible effect on any of the measured parameters.
Significant main effects of glycine infusion (G) included increments in MAP, GFR, SNGFR, SNPF, and EFP, and decreases in Hct, 7rA, and ER. Pretreatment with CsA significantly enhanced the effect of glycine on MAP but attenuated the effect of glycine on GFR and obliterated the effect of glycine on SNGFR. The mitigating influence of CsA on the response ofglomerular filtration to glycine resulted from the sum of interactions between CsA and glycine in determining SNPF and LpA, although large variance in SNPF among CsA-G rats and in LpA among CsA-B rats prevented these interactions from achieving statistical significance by ANOVA.
Co-treatment with ARG in rats receiving CsA restored the responsiveness of GFR and SNGFR to glycine, with the filtration response to G among A/CsA rats similar to that of CON animals. The mechanisms by which arginine restored the response of SNGFR to glycine among animals receiving CsA involved a sum ofeffects on the reactions ofSNPF and LpA to glycine, although again, the individual interactions were not statistically significant. The vasodilatory response to glycine observed in control animals as manifested by a decrease in AR may have been masked by the autoregulatory response to the increase in MAP associated with glycine in rats treated with CsA and ARG.
Proximal tubular reabsorption before and during glycine infusion. Among the main effects of CsA were a significant increase in fractional reabsorption (FR) within the proximal tubule and an insignificant decrease in absolute reabsorption (APR) from the same segment. Neither of these effects were conditioned by L-arginine, which did not singularly influence either index ofproximal reabsorption. Glycine significantly depressed FR while tending to increase APR overall. Pretreatment with CsA, however, significantly altered the proximal tubular response to glycine infusion, promoting a decrement in FR and causing an actual decline in APR. This effect ofCsA on the tubular response to glycine was attenuated by co-administration ofL-arginine, which, as mentioned above, had no direct effect on proximal reabsorption, and did not interact directly with G.
Effect of L-NMMA administration. The effect of G on SNGFR among A/CsA rats was blocked by prior administration of L-NMMA (31±3 vs. 30±3 nl/min). In this group, G caused APR to decrease (14±1 to 10±1 nl/min, P < 0.05). These results suggest that the effects ofarginine feeding in CsA rats are mediated by increases in NO.
Plasma and intrarenal angiotensin II levels. Plasma and kidney All values are depicted in Table II . On a per-weight basis, renal tissue exhibited more All than did plasma. In comparison to control animals, plasma All concentration among those receiving CsA was higher before glycine and lower during glycine infusion. Glycine appeared to decrease plasma All concentrations in CsA-treated, but not control animals.
While there was a subtle main tendency for CsA to increase plasma All, there was a strong main tendency for CsA to decrease the concentration of All in renal tissue. These effects of CsA were not affected by L-arginine in the absence of glycine. Glycine infusion was associated with a major increase in kidney All which obscured the effect ofCsA in animals not receiving L-arginine. Among those receiving glycine, however, L-arginine feeding led to a further increment in kidney All among CON rats, such that the effect of CsA reemerged. Probabilities referred to as "main effects" are those associated with a specific treatment independent of other treatments. An "interaction between treatments" refers to the probability of one treatment affecting the response to another, i.e., "CsA*Arg" refers to the probability that treatment with L-arginine conditions the response to CsA, etc.
Discussion
We previously reported that the functional nephrotoxicity of chronically administered CsA is mediated by a major decline in effective filtration pressure and a minor decrement in nephron plasma flow, each the consequence of uncompensated preglomerular vasoconstriction (6) . These findings have been confirmed by others (7) and are reproduced in the present studies. A number ofcontrol systems are known to participate in maintaining a proper balance between pre-and postglomerular resis-tances, and the present studies provide evidence that CsA interferes with at least two of these influences. First, CsA interferes with normal endothelium-dependent relaxation ofthe afferent arteriole. Second, CsA appears to interfere with the compensatory generation of All within the kidney, a response which is required to maintain efferent arteriolar tone and protect glomerular capillary hydrostatic pressure. The notion that CsA nephrotoxicity involves damage to the vascular endothelium has been posed by others (27) . Zoja et al. (8) reported time-and dose-dependent alterations in bovine endothelial cells exposed to CsA in culture. Incubation with CsA impairs endothelium dependent relaxation in response to acetylcholine in isolated resistance vessels from humans (28) and CsA treatment impairs subsequent ex vivo vasodilatory response to acetylcholine in arteries from rats (9-1 1 ). Kon et al. (27) reported that renal vasoconstriction after acute infusion of CsA in the rat was prevented by prior administration of an antibody to the endothelium-derived vasoconstrictor, endothelin (27) . The present study adds to this body of knowledge by providing in vivo evidence for impaired renal activity of the endothelium dependent relaxing factor and natural antagonist to endothelin and All, nitric oxide (NO). This evidence is manifested (a) by afferent arteriolar vasoconstriction which is prevented by dietary supplementation with the NO substrate, L-arginine, (b) a diminished glomerular hemodynamic response to glycine infusion, and (c) restoration of the response to glycine by treatment with L-arginine.
Arima et al. (29) has reported that an intact NO system exerts a greater influence over the afferent than the efferent glomerular arteriole. A depressed glomerular capillary hydro- The present studies also suggest that CsA interrupts the relationship ofplasma to kidney All concentration. The role of the renin-angiotensin system in CsA nephrotoxicity has been a subject of controversy (6). Barros originally observed an increase in APwith decreases in LpA and SNPF in accounting for the decline in SNGFR which occurred in response to a single intravenous bolus of CsA, a pattern strikingly similar to that observed with All infusion (34) . It has been further suggested that the effects of CsA in this model could be partially prevented by angiotensin converting enzyme inhibition with captopril (34, 35) . Antithetically, our findings in this short-term chronic model ofCsA nephrotoxicity suggest that CsA administration resulted in a relative state of intrarenal All deficiency, resulting in a failure of the efferent arteriole to compensate for preglomerular vasoconstriction, leading to a major decline in EFP and, subsequently, SNGFR. Indeed, by direct measurements, the present studies have demonstrated that CsA suppresses the quantity of All in renal tissue independent of plasma All concentration. However, since glycine infusion substantially increased kidney All in all groups while its glomerular hemodynamic effects were blunted in CsA rats, the glomerular hemodynamic derangements resulting from CsA administration cannot be attributed solely to All deficiency.
Loss of the vasodilatory response to glycine has been demonstrated in other models of renal injury in the rat including two-kidney one-clip Goldblatt hypertension (31), early diabetes mellitus (36) , and experimental glomerulonephritis (37) . In each ofthese cases, glycine infusion has been linked to a paradoxical decline in proximal tubular reabsorption, raising the possibility that the afferent arteriolar relaxation which usually results from glycine infusion was neutralized by a concurrent increase in delivery of fluid to the distal nephron with ensuing activation (or disinhibition) of the tubuloglomerular feedback (TGF) system. Consistent with this theme, Woods et al. have reported that renal functional reserve is impaired in dogs with experimental Fanconi syndrome or when TGF activity is diminished by a loop diuretic (38, 39) . This pattern of glomerular and tubular response to glycine infusion also occurs in normal rats treated with the NO synthase inhibitor, L-NMMA ( 12) , suggesting that NO inhibition per se interferes with the normal tubular response to glycine. Interestingly, CsA nephrotoxicity provides another example in which the failure of glycine to induce renal vasodilation is accompanied by a decrease in proximal reabsorption. Furthermore, L-arginine restores the tubular as well as glomerular hemodynamic response to glycine in this model of CsA nephrotoxicity.
Although inhibition of TGF and stimulation of NO have been previously discussed, the precise mechanism whereby glycine infusion leads to renal vasodilation has not been fully elucidated. We have previously observed that the administration of competitive antagonists to All normalizes the glomerular and tubular responses to glycine during treatment with L-NMMA (12) , suggesting that NO normally functions within the proximal nephron to antagonize the anti-reabsorptive effects of All (40) . Armed with the new knowledge that glycine increases intrarenal All concentration, we now propose that infusion ofthis substance induces parallel increases in NO and All activity with the glomerular hemodynamic outcome contingent upon the net balance between the two systems. When the balance favors NO, proximal reabsorption increases, TGF activity is minimized, vasodilation ensues, and GFR increases. When the balance favors All, proximal reabsorption declines, TGF is diminished and the vasodilatory influence of NO is overcome.
In conclusion, the present studies demonstrate that glycine infusion, while a stimulus to NO, also causes tissue All levels to increase, that CsA nephrotoxicity is associated with decreased quantities ofangiotensin II within renal tissue, and that dietary supplementation with L-arginine restores the glomerular and tubular responses to glycine infusion after short-term CsA treatment. CsA causes preglomerular vasoconstriction mediated in part by inadequate NO activity, and a decline in effective filtration pressure mediated in part by an inadequate All response to glomerular hypotension. While glycine induces an increase in renal All concentration, a normal NO response to glycine is inhibited by CsA such that no increase in GFR occurs. A pathogenetic role for abnormal nitric oxide activity in this in vivo model of chronic CsA nephrotoxicity is thus suggested. 
